1549 related articles for article (PubMed ID: 28029640)
1. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
2. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
3. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
4. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
[TBL] [Abstract][Full Text] [Related]
5. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
[No Abstract] [Full Text] [Related]
6. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
7. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN
Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
9. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
10. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
[TBL] [Abstract][Full Text] [Related]
15. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
17. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
20. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]